Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-000950-39
    Sponsor's Protocol Code Number:BAY94-8862/17530
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-07-31
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-000950-39
    A.3Full title of the trial
    A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.
    Estudio fase III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, dirigido por eventos, para evaluar la eficacia y seguridad de finerenona, asociada al tratamiento estándar, en la reducción de la morbilidad y mortalidad cardiovascular en pacientes con Diabetes Mellitus Tipo 2 y diagnóstico clínico de nefropatía diabética.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
    Eficacia y seguridad de finerenona en pacientes con Diabetes Mellitus Tipo 2 y diagnóstico clínico de nefropatía diabética
    A.3.2Name or abbreviated title of the trial where available
    FIGARO-DKD
    A.4.1Sponsor's protocol code numberBAY94-8862/17530
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBayer HealthCare AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer HealthCare AG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBayer HealthCare AG
    B.5.2Functional name of contact pointBayer Clinical Trials Contact
    B.5.3 Address:
    B.5.3.1Street AddressCTP Team/Ref:"EU CTR"/ Bayer Pharma AG
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code13342
    B.5.3.4CountryGermany
    B.5.4Telephone number0034.900102372
    B.5.6E-mailclinical-trials-contact@bayerhealthcare.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 94-8862 IR tablet 10 mg
    D.3.2Product code BAY 94-8862 coated tablet 10 mg
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFinerenone
    D.3.9.1CAS number 1050477-31-0
    D.3.9.2Current sponsor codeBAY 94-8862 micronized
    D.3.9.3Other descriptive nameBAY 94-8862
    D.3.9.4EV Substance CodeSUB30924
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 94-8862 IR tablet 20 mg
    D.3.2Product code BAY 94-8862 coated tablet 20 mg
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFinerenone
    D.3.9.1CAS number 1050477-31-0
    D.3.9.2Current sponsor codeBAY 94-8862 micronized
    D.3.9.3Other descriptive nameBAY 94-8862
    D.3.9.4EV Substance CodeSUB30924
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Type II Diabetes Mellitus and Diabetic Kidney Disease
    Diabetes Mellitus Tipo 2 y diagnóstico clínico de nefropatía diabética
    E.1.1.1Medical condition in easily understood language
    Type II Diabetes Mellitus and Diabetic Kidney Disease
    Diabetes Mellitus Tipo 2 y diagnóstico clínico de nefropatía diabética
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level PT
    E.1.2Classification code 10061835
    E.1.2Term Diabetic nephropathy
    E.1.2System Organ Class 10038359 - Renal and urinary disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality and morbidity in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
    ? Demostrar si, añadida al tratamiento estándar, finerenona es superior al placebo en retrasar la aparición del primer evento de morbimortalidad cardiovascular en sujetos con diabetes mellitus de tipo 2 y el diagnóstico clínico de nefropatía diabética.
    E.2.2Secondary objectives of the trial
    - Delays the time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in estimated glomerular filtration rate (eGFR) of ?40% from baseline over at least 4 weeks or renal death
    - Delays the time to all-cause hospitalization
    - Delays the time to all-cause mortality
    - Change in UACR from baseline to Month 4
    - Delays the time to first occurrence of the following composite endpoint:
    onset of kidney failure, a sustained decrease in eGFR of ?57% from baseline over at least 4 weeks or renal death.
    -Retrasa el tiempo transcurrido hasta la primera aparición del siguiente criterio de valoración compuesto: aparición de insuficiencia renal, reducción mantenida de la filtración glomerular estimada (FGe) ? 40 % respecto al periodo basal durante al menos 4 semanas o muerte por causas renales
    - Retrasa el tiempo transcurrido hasta la hospitalización por cualquier causa
    - Retrasa el tiempo transcurrido hasta la muerte por cualquier causa
    - Cambio en el cociente albúmina/creatinina (CAC) en orina respecto al periodo basal hasta el mes 4
    - Retrasa el tiempo transcurrido hasta la primera aparición del siguiente criterio de valoración compuesto:
    aparición de insuficiencia renal, reducción mantenida de la FGe ? 57 % respecto al periodo basal durante al menos 4 semanas o muerte por causas renales.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Men or women aged 18 years and older. The lower age limit may be higher if legally required in the participating country.
    - Women of childbearing potential can only be included in the study if a pregnancy test is negative at the screening visit and if they agree to use adequate contraception. Adequate contraception is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate) or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: FSH levels > 40 mIU/mL and estradiol < 20 pg/mL] or have had surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy.
    -Subjects with type 2 diabetes mellitus as defined by the American Diabetes Association
    -Subjects with a clinical diagnosis of DKD based on either of the following criteria at the Run-in and Screening Visit:
    Persistent high albuminuria defined as UACR of >= 30 mg/g (>= 3.4 mg/mmol) but < 300 mg/g (< 33.9 mg/mmol) in 2 out of 3 first morning void samples and eGFR >= 25 but <= 90 mL/min/1.73 m2 (CKD-EPI)
    OR
    Persistent very high albuminuria defined as UACR of >= 300 mg/g (>=33.9 mg/mmol) in 2 out of 3 first morning void samples and eGFR >=60 mL/min/1.73 m2 (CKD-EPI)
    -Prior treatment with ACEIs and ARBs as follows:
    For at least 4 weeks prior to the Run-in Visit, subjects should be treated with either an ACEI or ARB, or both
    Starting with the Run-in Visit, subjects should be treated with only an ACEI or ARB
    For at least 4 weeks prior to the Screening Visit, subjects should be treated with the maximum tolerated labeled dose (but not below the minimal labeled dose) of only an ACEI or an ARB (not both) preferably without any adjustments to dose or choice of agent or to any other antihypertensive or antiglycemic treatment
    - Serum potassium <= 4.8 mmol/L at both the Run-in and the Screening Visit
    - Hombres o mujeres a partir de 18 años
    - Sujetos con diabetes mellitus tipo 2 según la definición de la American Diabetes Association
    - Diagnóstico de nefropatía diabética con al menos uno de los criterios siguientes en las visitas de lavado y selección:
    - albuminuria elevada persistente .
    o
    - albuminuria muy elevada persistente .
    - Tratamiento previo durante al menos 4 semanas antes de la visita de selección bien con un inhibidor de la enzima convertidora de la angiotensina o bien con un antagonista del receptor de la angiotensina a la dosis máxima tolerada autorizada, preferiblemente sin ajustes de la dosis ni elección de otro fármaco o tratamiento.
    - Potasio sérico ? 4,8 mmol/l.
    E.4Principal exclusion criteria
    - Known significant non-diabetic renal disease, including clinically relevant renal artery stenosis
    - Uncontrolled arterial hypertension with mean sitting systolic blood pressure (SBP) >= 170 mmHg or mean sitting diastolic blood pressure (DBP) ? 110 mmHg at the Run-in Visit or mean sitting SBP ?160 mmHg or mean sitting DBP >=100 mmHg at the Screening Visit
    - Clinical diagnosis of chronic HFrEF and persistent symptoms (NYHA class II ? IV) at Run in visit (class 1A recommendation for MRAs)
    - Dialysis for acute renal failure within 12 weeks of Run-in visit
    - Renal allograft in place or scheduled kidney transplant within next 12 months from the Run-in visit
    - HbA1c > 12% (> 108 mmol/mol) at the Run-in Visit or Screening Visit
    - Nefropatía no diabética significativa confirmada, incluida estenosis de la arteria renal clínicamente significativa.
    - Hipertensión arterial no controlada (es decir, PAS media en sedestación ? 170 mm Hg, PAD en sedestación ? 110 mm Hg en la visita de lavado, o PAS media en sedestación ? 160 mm Hg, PAD en sedestación ? 100 mm Hg en la visita de selección)
    - Diagnóstico clínico de de insuficiencia cardiaca con fracción de eyección reducida (ICFEr) crónica y síntomas persistentes (clase II ? IV de la NYHA) en la visita de lavado (recomendación de clase 1A para antagonistas del receptor de mineralocorticoides: ARM)
    - Diálisis por insuficiencia renal aguda en las 12 semanas anteriores a la visita de lavado
    - Aloinjerto renal realizado o trasplante renal programado en los 12 meses siguientes
    - HbA1c > 12 %.
    E.5 End points
    E.5.1Primary end point(s)
    Time to first occurrence of the composite endpoint of CV death or non-fatal CV event (i.e. myocardial infarction, stroke, or hospitalization for HF).
    Tiempo transcurrido hasta la primera aparición del criterio de valoración compuesto de muerte cardiovascular (CV) o acontecimiento CV no mortal (es decir, infarto de miocardio, ictus u hospitalización por insuficiencia cardíaca).
    E.5.1.1Timepoint(s) of evaluation of this end point
    From randomization (Visit 1) until the end of study following the study termination decision, approximately from 18 to 36 months
    Desde el día de la aleatorización (visita 1) hasta la visita de final del estudio tras la decisión de finalización del estudio, aproximadamente entre los 18 y los 36 meses.
    E.5.2Secondary end point(s)
    Time to first occurrence of the following composite endpoint:
    onset of kidney failure, a sustained decrease of eGFR >= 40% from baseline over at least 4 weeks or renal death
    Time to all-cause hospitalization
    Time to all-cause mortality
    Change in UACR from baseline to Month 4
    Time to first occurrence of the following composite endpoint: onset of kidney failure, a sustained decrease in eGFR of >= 57% from baseline over at least 4 weeks or renal death.
    Tiempo transcurrido hasta la primera aparición del criterio de valoración compuesto:
    aparición de insuficiencia renal, reducción mantenida de la filtración glomerular estimada (FGe) ? 40 % respecto al periodo basal durante al menos 4 semanas o muerte por causas renal
    Tiempo transcurrido hasta la hospitalización por cualquier causa
    Tiempo transcurrido hasta la muerte por cualquier causa
    Cambio en el cociente albúmina/creatinina en orina respecto al periodo basal hasta el mes 4*
    Tiempo transcurrido hasta la primera aparición del siguiente criterio de valoración compuesto:
    aparición de insuficiencia renal, reducción mantenida de la FGe ? 57 % respecto al periodo basal durante al menos 4 semanas o muerte por causas renales.
    E.5.2.1Timepoint(s) of evaluation of this end point
    For all endpoints:
    From randomization (Visit 1) until the end of study following the study termination decision, approximately from 18 to 36 months

    Except endpoint*:
    Frombaseline / randomization to Month 4
    Para todos los eventos:
    Desde aleatorización (Visita 1) hasta la visita de final del estudio tras la decisión de finalización del estudio, aproximadamente entre los 18 y los 36 meses

    Excepto evento*:
    Desde visita basal/aleatorización hasat mes 4.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA300
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Belgium
    Brazil
    Bulgaria
    Canada
    Chile
    China
    Colombia
    Czech Republic
    Denmark
    Finland
    France
    Germany
    Greece
    Hong Kong
    Hungary
    Israel
    Italy
    Japan
    Korea, Republic of
    Lithuania
    Netherlands
    New Zealand
    Norway
    Philippines
    Poland
    Portugal
    Russian Federation
    Saudi Arabia
    Singapore
    South Africa
    Spain
    Sweden
    Switzerland
    Taiwan
    Thailand
    Turkey
    Ukraine
    United Kingdom
    United States
    Vietnam
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último sujeto
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months36
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months36
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 7630
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5170
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Patients unable to sign can be consented by legally acceptable representative/guardian/parent
    Pacientes incapaces de firmar pueden consentir mediante un representante legal autorizado
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state407
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 6000
    F.4.2.2In the whole clinical trial 12800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard treatment
    Tratamiento estándar
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-10-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-10-05
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-02-02
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA